[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"weight-body\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:weight-body":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,94,122,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820",false,"NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)",true,"FEMALE","18 Years","60 Years",{"count":22,"type":23},140,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[29,30,31,32,33,34,35,36,37,38,39,40,41],"Breast Pain","Mastalgia","Back Pain","Back Pain, Low","Neck Pain","Chest Pain","Activity, Motor","Healthy Aging","Weight, Body","Inflammation","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","RECRUITING","2026-05-28",{"date":45,"type":46},"2026-06-02","ACTUAL",{"date":48,"type":46},"2026-05-17",{"date":50,"type":23},"2029-09",{"name":52,"class":53},"University of Houston","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":62,"minAge":19,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":24,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":54},"100539115","endoscopic-sleeve-gastroplasty-technique-comparison-for-weight-loss-100539115","NCT06299644","Endoscopic Sleeve Gastroplasty Technique Comparison for Weight Loss","Endoscopic Sleeve Gastroplasty Technique Comparison for Weight Loss Using the Endomina Plicating Device: A Randomized Trial","Inclusion Criteria:\n\n1. Patients with 18-65 years of age\n2. BMI ≥ 30 kg\u002Fm2\n3. Capable of giving informed consent and available to return for follow-up visit\n\nExclusion Criteria:\n\n1. Untreated H. pylori infection\n2. Active gastric or duodenal ulceration\n3. Malignant or premalignant gastric diseases (such as intestinal metaplasia, high grade dysplasia, gastric adenocarcinoma, or gastrointestinal stromal tumor (GIST))\n4. Severe reflux esophagitis (Los Angeles Classification (LA) Grade C or D)\n5. Esophageal or gastric varices and\u002For portal hypertensive gastropathy\n6. Gastroparesis\n7. History of gastric surgery\u002Fendoscopic procedure\n8. Active psychological issues preventing participation in a lifestyle modification program\n9. Known history of endocrine disorders affecting weight (uncontrolled hypothyroidism)\n10. Severe coagulopathy\n11. Active smoking\n12. Substance abuse\n13. Serious health condition that increased risk of anesthesia and\u002For endoscopic procedure\n14. Pregnancy or lactation\n15. Patients who require Non-Steroidal Anti-inflammatory Drugs (NSAID) use","ALL","65 Years",{"count":65,"type":23},10,[67],"NA","The Investigators propose suture plication placement at the distal gastric body drives a significant portion of weight loss in endoscopic sleeve and sutures only need to be placed in the distal gastric body. Therefore, in this pilot study, the investigators aim to compare \"belt\" with \"belt and suspenders\" plication pattern using the Endomina system to determine percent total weight loss.",[70,71,72,37],"Obesity","Obesity, Morbid","Metabolic Disease",[74,75,76,77,78,79,80,81,82,83],"Endoscopic Bariatric and Metabolic Therapies (EBMT)","Endoscopic Bariatric Therapies (EBT)","Gastric emptying","Endoscopic Suturing","endoscopic sleeve gastroplasty (ESG)","Weight Loss","Bariatric Endoscopy","Weight Management","Endoscopic plication","Gastric plication","NOT_YET_RECRUITING","2025-11-25",{"date":87,"type":46},"2025-12-02",{"date":89,"type":23},"2026-09",{"date":91,"type":23},"2028-05",{"name":93,"class":53},"Brigham and Women's Hospital",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":62,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":24,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":54},"100550396","phase-1-prevention-of-progression-of-prediabetes-obesity-and-cv-risk-100550396","NCT06446531","Prevention of Progression of Prediabetes, Obesity and CV Risk","Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in Hispanics","Pre-DM","Inclusion Criteria:\n\n1. Patients will have an established diagnosis of pre-Diabetes Mellitus (DM) before the screening visit, documented by an acceptable modality in the last 6 months.\n2. Age ≥ 18 years old\n3. Body Mass Index (BMI)=25-40 kg\u002Fm2\n4. Glycated Hemoglobin (HbA1c) = 5.7-6.4%\n5. Blood Pressure (BP) \\\u003C160\u002F100\n6. Estimated Glomerular Filtration Rate (eGFR) ≥30 ml\u002Fmin•1.73m2\n7. Body weight must be stable (±5 pounds) over the last 3 months.\n8. Oral diuretics, if prescribed to the patient according to local guidelines and discretion of the investigator, should be stable for at least 1 week prior to randomization.\n9. Hispanic ethic group\n10. Willing to adhere to medication regimen for up to 6 months.\n11. Male or female, if female, met these criteria:\n\n    1. Not pregnant or breast-feeding\n    2. Negative pregnancy test result at visit 1 (screening)\n    3. During the entire study, women of childbearing potential (WOCBP) including peri-menopausal women who have a menstrual period within 1 year must practice appropriate, and effective birth control, either implants or pills, or a vasectomized partner prior to receiving the first dose of study medication\n12. Does not suffer from severe claustrophobia\n13. No contraindication for Magnetic Resonance Imaging (MRI) (metal plates, screws, shrapnel, pins, or cardiac pacemaker)\n\nExclusion Criteria:\n\n1. Patients currently on one of the selected therapies\n2. Extended diagnoses with Type 2 Diabetes\n3. Pregnancy, lactation, women of childbearing age (WOCBA) unwilling to use contraception\n4. Known allergy\u002Fsensitivity to study drugs or their ingredients\n5. Major oncologic diagnosis in the last 5 years\n6. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n7. Inability or unwillingness of individual or legal guardian\u002Frepresentative to give written informed consent\n8. Major organ or metabolic diseases, or physical limitations that will not allow the subject to complete the study\n9. Myocardial infraction, coronary artery bypass graft surgery, or other major cardiovascular event in the past 60 days\n10. Heart transplant recipient or listed for a heart transplant\n11. Currently implanted left ventricular assist device\n12. Cardiomyopathy based on infiltrative or cumulative hypertrophic obstructive cardiomyopathy or known pericardial constriction\n13. Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial period\n14. Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support within 1 week of screening and during the screening period prior to randomization\n15. Implanted cardioverter defibrillator within 3 months prior to screening\n16. Cardiac resynchronization therapy",{"count":103,"type":23},64,[26],"The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.",[107,37,108],"Pre-Diabetes","Cardiovascular Diseases",[110,111,112],"Affordable strategies","Prevention of progression","Hispanic","2025-11-10",{"date":115,"type":46},"2025-11-12",{"date":117,"type":46},"2024-09-11",{"date":119,"type":23},"2027-07",{"name":121,"class":53},"The University of Texas Health Science Center at San Antonio",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":62,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100508345","patient-recorded-indexing-measurements-100508345","NCT05899205","Patient Recorded Indexing Measurements","PRIMs","Inclusion Criteria:\n\n* Age ≥ 18\n* Diagnosed with cancer\n* Planned for curative-intent surgery or neo-adjuvant chemotherapy\n\nExclusion Criteria:\n\n* ASA-classification V,\n* severe liver cirrhosis Child grade C,\n* end stage renal disease requiring dialysis,\n* severe heart disease New York Heart Association class IV,\n* chronic obstructive pulmonary disease (COPD) requiring (home)oxygen therapy,\n* Patients must be \"mobile\". They may not be bedridden or in a wheelchair.",{"count":130,"type":23},300,"OBSERVATIONAL","Rationale: One of the greatest challenges in the field of cancer treatment is cachexia, a multifactorial syndrome characterized by substantial loss of body weight (muscle and fat mass), leading to progressive functional impairment. Cancer cachexia significantly impairs quality of life and survival as well as treatment outcome. Despite its considerable relevance for the prognosis of cancer patients, the diagnosis of cachexia is problematic. The current consensus definition of cancer cachexia is based on weight loss over the last six months. In practice, this is assessed by subjective reporting by the patient, which is subject to error and bias. Novel technologies enable accurate, standardized, and objective assessment of body weight and physical activity by newly diagnosed cancer patients in the home situation. Because of the increasing implementation of neo-adjuvant treatment strategies that offer an extended time-window for the collection of these data, there is a great opportunity to use this information in risk analyses by treating physicians, optimization of pre-habilitation programs, and in the shared-decision making process with the patient.\n\nObjective: The central aim of the 'Patient-Recorded Indexing MeasurementS' (PRIMS) study is to improve the accuracy of the diagnosis of cachexia in patients with cancer. This aim will be achieved by focusing on two objectives. The primary objectives are to compare self-reported and objectively measured pre-treatment weight change. The secondary objectives are to define host phenotypes and to investigate longitudinal associations between body weight and physical activity patterns.\n\nStudy design: Explorative pilot study\n\nStudy population: Patients ≥18 years old undergoing curative-intent chemotherapy or surgery for cancer. Patients will be included in two referral centers specialized in treatment of patients with upper gastrointestinal, hepatobiliary, pancreatic, colorectal, and ovarian cancer.\n\nMain study parameters\u002Fendpoints: The primary endpoint is body weight change over time. Objectively measured body weight will be compared to subjectively reported body weight change. Their respective association with treatment-related adverse events and survival will be investigated. Survival will be calculated from date of start of treatment until death. Chemotherapy related adverse event will be recorded using the Common Terminology Criteria for Adverse Events. Postoperative adverse events will be scored according to the Clavien-Dindo classification.\n\nSecondary endpoints: The secondary endpoints will be the association between other cachexia-related parameters that are investigated in the study and adverse events \u002F survival. Other parameters include physical activity over time, using accelerometry, baseline physical assessment, anthropometric measurements, body composition, and laboratory results. Besides this, other endpoints that will be assessed are disease-free survival (calculated from the first day of treatment until first recurrence) and response to chemotherapy according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria.",[134,135,37],"Cachexia","Cancer",[137,138,139,140,141,142],"Cancer cachexia","Physical activity","Body weight","Body composition","Functional mobility","Pre-treatment assessment","2025-08-19",{"date":145,"type":46},"2025-08-24",{"date":147,"type":46},"2021-06-01",{"date":149,"type":23},"2027-06-01",{"name":151,"class":53},"Academisch Ziekenhuis Maastricht",2,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":62,"minAge":19,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":24,"phases":162,"briefSummary":163,"conditions":164,"keywords":168,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100537754","machine-learning-and-3d-image-based-modeling-for-body-weight-estimation-100537754","NCT06281938","Machine Learning and 3D Image-based Modeling for Body Weight Estimation.","Machine Learning and 3D Image-based Modeling for Real-time Body Weight and Body Composition Estimation During Emergency Medical Care.","Inclusion Criteria:\n\n\\- Any patient presenting to the Emergency Department of the study site, who will require any form of weight-based intravenous drug therapy, and who will be admitted to the hospital.\n\nExclusion Criteria:\n\n* Patients who are unable to provide consent.\n* Patients whose medical treatment could be negatively impacted by participation in the study.",{"count":161,"type":23},320,[67],"The goal of this randomized controlled clinical trial is to \\[learn about, test, compare etc.\\] in critically ill or injured cohorts of patients presenting to the Emergency Department. The main question\\[s\\] it aims to answer are:\n\n* Are weight estimates from a 3D camera system more accurate than standard methods of weight estimation?\n* Do patients who receive weight estimates with a 3D camera system have fewer drug dosing errors than patients receiving standard care?\n\nParticipants will either receive a weight estimate using a 3D camera system, or standard methods of care.\n\nResearchers will compare the 3D camera group to those with standard care to see if the weight estimates are more accurate, to see if drug dosing is more accurate, and to compare the incidence of adverse events related to medications in each group.",[165,37,166,167],"No Specific Conditions","Drug Dose","Weight-Estimation",[169,170,171,172,173,174],"weight estimation","drug dosing","3D camera","total body weight","lean body weight","ideal body weight","2025-06-05",{"date":177,"type":46},"2025-06-06",{"date":179,"type":23},"2026-06",{"date":181,"type":23},"2027-09",{"name":183,"class":53},"Florida Atlantic University"]